Overview

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

Status:
Recruiting

Trial end date:
2022-11-15

Target enrollment:

Participant gender:

Summary

In order to improve the survival rates and decrease progression of pancreatic advanced cancer, this study aims to evaluate the first line treatment approved for this disease (gemcitabine plus nab-paclitaxel) in combination with two experimental drugs, an inhibitor of the signaling pathway of Hedgehog and an immunotherapy drug able of blocking the CTLA-4 receptor.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Nelum Corp

Collaborators:

Agenus Inc.
Apices Soluciones S.L.

Treatments:

Gemcitabine
Paclitaxel